1. Remote blood collection from older adults in the Brain Health Registry for plasma biomarker and genetic analysis
- Author
-
Fockler, Juliet, Ashford, Miriam T, Eichenbaum, Joseph, Howell, Taylor, Ekanem, Aniekan, Flenniken, Derek, Happ, Alexander, Truran, Diana, Mackin, R Scott, Blennow, Kaj, Halperin, Eran, Coppola, Giovanni, Weiner, Michael W, and Nosheny, Rachel L
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Clinical Sciences ,Neurosciences ,Psychology ,Acquired Cognitive Impairment ,Clinical Research ,Aging ,Prevention ,Neurodegenerative ,Behavioral and Social Science ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Brain Disorders ,Dementia ,Alzheimer's Disease ,Neurological ,Humans ,Aged ,Alzheimer Disease ,Brain ,Biomarkers ,Cognitive Dysfunction ,Registries ,acceptability ,aging research ,Alzheimer's disease ,brain health registry ,education ,engagement ,ethnicity ,feasibility ,genetics ,internet ,plasma biomarkers ,race ,research registry ,Geriatrics ,Clinical sciences ,Biological psychology - Abstract
IntroductionUse of online registries to efficiently identify older adults with cognitive decline and Alzheimer's disease (AD) is an approach with growing evidence for feasibility and validity. Linked biomarker and registry data can facilitate AD clinical research.MethodsWe collected blood for plasma biomarker and genetic analysis from older adult Brain Health Registry (BHR) participants, evaluated feasibility, and estimated associations between demographic variables and study participation.ResultsOf 7150 participants invited to the study, 864 (12%) enrolled and 629 (73%) completed remote blood draws. Participants reported high study acceptability. Those from underrepresented ethnocultural and educational groups were less likely to participate.DiscussionThis study demonstrates the challenges of remote blood collection from a large representative sample of older adults. Remote blood collection from > 600 participants within a short timeframe demonstrates the feasibility of our approach, which can be expanded for efficient collection of plasma AD biomarker and genetic data.
- Published
- 2022